IBC Pharmaceuticals, Inc.
Records under this name other than the patents IBC Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 19 patents it holds.
Back to IBC Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,163,291 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses Term ended Term ended Aug 27, 2026 · From the USPTO record | Term ended | Term ended Aug 27, 2026 | From the USPTO record |
| US 7,550,143 | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses Term ended Term ended Jun 23, 2026 · From the USPTO record | Term ended | Term ended Jun 23, 2026 | From the USPTO record |
| US 7,666,400 | PEGylation by the dock and lock (DNL) technique Term ended Term ended Jun 1, 2026 · From the USPTO record | Term ended | Term ended Jun 1, 2026 | From the USPTO record |
| US 7,534,866 | Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses Term ended Ended no later than Apr 16, 2026 · Low confidence | Term ended | Ended no later than Apr 16, 2026 | Low confidence |
| US 10,022,427 | Interferon lambda-antibody complexes Term ended Term ended Apr 16, 2026 · From the USPTO record | Term ended | Term ended Apr 16, 2026 | From the USPTO record |
| US 9,272,029 | Interferon lambada-antibody complexes Term ended Term ended Apr 7, 2026 · From the USPTO record | Term ended | Term ended Apr 7, 2026 | From the USPTO record |
| US 7,871,622 | Stably tethered structures of defined compositions with multiple functions or binding specificities Term ended Term ended Mar 28, 2026 · From the USPTO record | Term ended | Term ended Mar 28, 2026 | From the USPTO record |
| US 9,540,435 | Stably tethered structures of defined compositions with multiple functions or binding specificities Term ended Ended no later than Mar 28, 2026 · From the USPTO record | Term ended | Ended no later than Mar 28, 2026 | From the USPTO record |
| US 7,527,787 | Multivalent immunoglobulin-based bioactive assemblies Term ended Term ended Mar 24, 2026 · From the USPTO record | Term ended | Term ended Mar 24, 2026 | From the USPTO record |
| US 7,858,070 | Multivalent immunoglobulin-based bioactive assemblies Term ended Term ended Mar 24, 2026 · From the USPTO record | Term ended | Term ended Mar 24, 2026 | From the USPTO record |